Antithrombotic Therapy and Hematoma Risk during Image-guided                     Core-Needle Breast Biopsy

Loving, Vilert A.; Johnston, Brian S.; Reddy, Denise; Welk, Leslie A.; Lawther, Hannah A.; Klein, Shayna C.; Cranford, Caroline M.; Reed, R. Christopher; Rangan, Pooja; Morris, Michael

doi:10.1148/radiol.220548

Cited by 11 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, discontinuing such a therapy before biopsy is associated with potential thromboembolic events and a delay in breast cancer diagnosis. However, recent reports have suggested that the risk of severe bleeding complications is low in patients on antithrombotic therapy [ 26 27 ]. Our findings emphasize the safety of a breast biopsy.…”

Section: Discussionmentioning

confidence: 99%

“…Our findings emphasize the safety of a breast biopsy. Nonetheless, patients who require full-dose antiplatelet drugs during biopsy or are elderly or if a radiologist plans to use a larger needle, the patient should be informed of a greater risk of hemorrhage and the radiologist should still take preventive steps to reduce bleeding irrespective of the anticoagulation status [ 26 27 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hemorrhagic Complications Following Ultrasound-Guided Breast Biopsy: A Prospective Patient-Centered Study

Yoen,

Chung,

Lee

et al. 2024

Korean J Radiol

View full text Add to dashboard Cite

Objective We aimed to evaluate the clinical and imaging factors associated with hemorrhagic complications and patient discomfort following ultrasound (US)-guided breast biopsy. Materials and Methods We prospectively enrolled 94 patients who were referred to our hospital between June 2022 and December 2022 for US-guided breast biopsy. After obtaining informed consent, two breast radiologists independently performed US-guided breast biopsy and evaluated the imaging findings. A hemorrhagic complication was defined as the presence of bleeding or hematoma on US. The patients rated symptoms of pain, febrile sensation, swelling at the biopsy site, and dyspnea immediately, 20 minutes, and 2 weeks after the procedure on a visual analog scale, with 0 for none and 10 for the most severe symptoms. Additional details recorded included those of nausea, vomiting, bleeding, bruising, and overall satisfaction score. We compared the clinical symptoms, imaging characteristics, and procedural features between patients with and those without hemorrhagic complications. Results Of 94 patients, 7 (7%) developed hemorrhagic complications, while 87 (93%) did not. The complication resolved with 20 minutes of manual compression, and no further intervention was required. Vascularity on Doppler examination ( P = 0.008), needle type ( P = 0.043), and lesion location ( P < 0.001) were significantly different between the groups. Patients with hemorrhagic complications reported more frequent nausea or vomiting than those without hemorrhagic complications (29% [2/7] vs. 2% [2/87], respectively; P = 0.027). The overall satisfaction scores did not differ between the two groups ( P = 0.396). After 2 weeks, all symptoms subsided, except bruising (50% 2/4 in the complication group and 25% [16/65] in the no-complication group). Conclusion US-guided breast biopsy is a safe procedure with a low complication rate. Radiologists should be aware of hemorrhagic complications, patient discomfort, and overall satisfaction related to this procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%